Minimed Group Inc opened lower at $18.23, compared with its previous close of $18.25. In the last trading session, the stock traded between $17.62 and $18.30. It showed a downward intraday trend.
An investment of $100 made 1 year ago in Minimed Group Inc is now worth
$ 96.65
Resulting in a loss of
$ 3.35 (3.35%)
Note: Past profits do not guarantee future returns.
Rating from 14 Analysts
Today's Change
$-0.38 (-2.08%)
Day High
$18.30
Day Low
$17.62
Day Open
$18.23
Prev Close
$18.25
Volume
26,34,185
1W Return
-2.08%
1M Return
1.88%
3M Return
-9.58%
6M Return
60.13%
1Y Return
-3.35%
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
1.56
PEG Ratio
-
ROE
-7.41%
ROCE
-5.75%
EPS (TTM)
-
1 Week
-2.08%
1 Month
1.88%
3 Months
-9.58%
6 Months
60.13%
9 Months
-3.35%
MiniMed names Kevin E. Lofton board chair after Medtronic split
Kevin E. Lofton named chair of MiniMed's Board of Directors. Amy Bricker and Tim L. Main join the board immediately. Board transition completes following separation from Medtronic. New board focuses on growth, innovation, and access to diabetes tech.
28 days agoMiniMed Q1 FY27 sales beat; analysts raise price targets
MiniMed Q1 FY27 net sales hit $843 million, beating consensus of $827.065 million. Organic revenue growth accelerated to 15.8%, driven by U.S. pump sales and international expansion. Analysts from B of A, Mizuho, and UBS raised price targets following the results. Company raised full-year organic revenue growth guidance to approximately 10.5%. Shares rose 7.1% to $24.01 on Wednesday after the earnings release.
2mo agoUBS raises Minimed Group price target to $28 on Buy rating
UBS maintains a Buy rating on Minimed Group (NASDAQ: MMED). Price target raised from $25 to $28. Analyst Patrick Wood leads the coverage update.
2mo agoMiniMed Flex ships in US with Abbott's Instinct sensor
MiniMed launches its Flex insulin pump with Abbott's Instinct sensor in the US, offering up to 15 days of wear. The FDA-cleared system uses SmartGuard automation and targets type 1 diabetics aged 7+ and type 2 adults. Real-world data from similar algorithms shows 80% Time in Range.
2mo agoMiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board
MiniMed appointed David Endicott and Linnea Burman to its Board of Directors on June 29, 2026, expanding the Board to 11 members. Endicott, CEO of Alcon, brings global healthcare leadership and public company experience. Burman, Senior Vice President at Medtronic, was designated by the majority shareholder to add MedTech operating depth.
4mo agoMiniMed launches Instinct sensors in Europe expanding choice
MiniMed has launched the MiniMed 780G and MiniMed Go systems integrated with Abbott's Instinct sensors in Europe. The rollout began this month following CE mark approval, offering users more choice without compromising clinical outcomes. The systems aim to improve glycemic control and therapy adherence through advanced automation and real-time insights.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 1 year ago in Minimed Group Inc is now worth
$ 96.65
Resulting in a loss of
$ 3.35 (3.35%)
Note: Past profits do not guarantee future returns.
